Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 11/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11394076 | 0.86 | MAOB (0.39) | IDO1AGXTMAOBMAOA | |
| SCHEMBL27693392 | 0.82 | MAOB (0.47) | IDO1AGXTMAOBMAOAHCAR2 | |
| SCHEMBL323966 | 0.81 | TAAR1 (0.52) | IDO1AGXTMAOBMAOAHCAR2 | |
| SCHEMBL28106982 | 0.81 | AGXT (0.64) | AGXTMAOBMAOATAAR1 | |
| SCHEMBL3251309 | 0.79 | IDO1 (0.52) | IDO1AGXTMAOBMAOAHCAR2 | |
| SCHEMBL7359415 | 0.78 | ENPP2 (0.50) | TAAR1 | |
| SCHEMBL27860858 | 0.78 | TSHR (0.43) | IDO1AGXTMAOBMAOA | |
| SCHEMBL28132843 | 0.78 | SLC6A2 (0.46) | IDO1AGXTMAOBMAOA | |
| SCHEMBL28344411 | 0.77 | IDO1 (0.69) | IDO1AGXTMAOBMAOAHCAR2 | |
| SCHEMBL9256367 | 0.77 | SOD1 (0.40) | IDO1AGXTMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016869-A1 | NOVEL DENDRIMER COMPOUND, A BIOCHIP USING THE SAME AND A FABRICATING METHOD THEREOF | POSTECH FOUNDATION (KR) | 2005-02-24 | — | — | WO | claimed |
| CN-112500324-B | Method for preparing thioamide compound | 浙江大学衢州研究院 | 2022-05-13 | — | — | CN | disclosed |
| CN-112500324-A | Method for preparing thioamide compound | 浙江大学衢州研究院 | 2021-03-16 | — | — | CN | disclosed |
| US-9169270-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-27 | — | — | US | disclosed |
| EP-2885307-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150158883-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICAL LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8974694-B2 | Liquid-crystal composition | JNC CORPORATION (JP) | 2015-03-10 | — | — | US | disclosed |
| WO-2014006585-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-09 | — | — | WO | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-20130188107-A1 | LIQUID-CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005016869-A1 | NOVEL DENDRIMER COMPOUND, A BIOCHIP USING THE SAME AND A FABRICATING METHOD THEREOF | POSTECH FOUNDATION (KR) | 2005-02-24 | — | — | WO | disclosed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | disclosed |
| CN-1020061-C | Insecticidal and acaricidal agents containing thiadiazines and process for their preparation | MITSUI TOATSU CHEMICALS (JP) | 1993-03-17 | — | — | CN | disclosed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | disclosed |
| CN-1039242-A | The preparation method of novel thiadiazine and the sterilant and the miticide that contain this type of thiadiazine | MITSUI TOATSU CHEMICALS (JP) | 1990-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | IDO1 3181/4885AGXT 2967/4885MAOB 2140/4885 |
| US-20150158883-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | IDO1 764/4885AGXT 4234/4885MAOB 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.